The effect of N-acetylcysteine on blood pressure and markers of cardiovascular risk in non-diabetic patients with chronic kidney disease: A placebo-cotrolled, randomized, cross-over study

Medical Science Monitor

Volumn 16, Issue 7, 2010, Pages 13-18

  Renke, Marcin ^a   Tylicki, Leszek ^a   Rutkowski, Przemysław ^a   Larczynski, Wojciech ^a   Neuwelt, Alexander ^b   Aleksandrowicz, Ewa ^a   Łysiak Szydłowska, Wieśawa ^a   Rutkowski, Bolesław ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Albuminuria; Blood pressure; Chronic kidney disease; Homocyteine; N acetylcysteine

Indexed keywords

ACC 600; ACETYLCYSTEINE; ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HOMOCYSTEINE; HYDROCHLOROTHIAZIDE; PLACEBO; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; PROTEIN; SCAVENGER; SODIUM;

ADD ON THERAPY; ADULT; ALBUMINURIA; AMINO ACID BLOOD LEVEL; ARTICLE; BLOOD PRESSURE MONITORING; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DISEASE MARKER; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; MALE; PATIENT COMPLIANCE; PROTEIN INTAKE; RANDOMIZED CONTROLLED TRIAL; SODIUM EXCRETION; SODIUM INTAKE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; ADOLESCENT; AGED; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; DIABETES MELLITUS; KIDNEY FUNCTION TEST; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; RISK FACTOR;

ACETYLCYSTEINE; ADOLESCENT; ADULT; AGED; ALBUMINURIA; BIOLOGICAL MARKERS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CROSS-OVER STUDIES; DIABETES COMPLICATIONS; FEMALE; FREE RADICAL SCAVENGERS; HOMOCYSTEINE; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PLACEBOS; PROTEINS; RISK FACTORS; SODIUM; YOUNG ADULT;

EID: 77954779155     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Foley RN, Parfrey PS: Cardiovascular disease and mortality in ESRD. JNephrol, 1998; 11(5): 239-452.
2. Weiner DE, Tighiouart H, Amin MG et al: Chronic kidney disease as arisk factor for cardiovascular disease and all-cause mortality: a pooledanalysis of community-based studies. J Am Soc Nephrol, 2004; 15(5):1307-153.
3. Shishehbor MH, Oliveira LP, Lauer MS et al: Emerging cardiovascularrisk factors that account for a significant portion of attributable mortalityrisk in chronic kidney disease. Am J Cardiol 2008, 101(12): 1741-464.
4. Tylicki L, Rutkowski P, Renke M et al: Triple Pharmacological Blockadeof the Renin-Angiotensin-Aldosterone System in Nondiabetic CKD: AnOpen-Label Crossover Randomized Controlled Trial. Am J Kidney Dis,2008; 52(3): 486-935.
5. Renke M, Tylicki L, Rutkowski P et al: Low-dose dual blockade of therenin-angiotensin system improves tubular status in non-diabetic proteinuricpatients. Scand J Urol Nephrol, 2005; 39(6): 511-176.
6. Tylicki L, Larczynski W, Rutkowski B: Renal protective effects of the renin-angiotensin-aldosterone system blockade: from evidence-based approachto perspectives. Kidney Blood Press Res, 2005; 28: 230-427.
7. Rutkowski P, Tylicki L, Renke M et al: Low-dose dual blockade of therenin-angiotensin system in patients with primary glomerulonephritis. Am J Kidney Dis, 2004; 43(2): 260-688.
8. Mann JF, Gerstein HC, Pogue J et al: Renal insufficiency as a predictorof cardiovascular outcomes and the impact of ramipril: the HOPE randomizedtrial. Ann Intern Med, 2001; 134(8): 629-369.
9. Sarnak MJ, Levey AS: Cardiovascular disease and chronic renal disease:a new paradigm. Am J Kidney Dis, 2000; 35(4 Suppl.1): S117-3110.
10. Canaud B, Cristol J, Morena M et al: Imbalance of oxidants and antioxidantsin haemodialysis patients. Blood Purif, 1999; 17(2-3): 99-10611.
11. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM: The elephant inuremia: oxidant stress as a unifying concept of cardiovascular diseasein uremia. Kidney Int, 2002; 62(5): 1524-3812.
12. Sies H: Oxidative stress: oxidants and antioxidants. Exp Physiol, 1997;82(2): 291-9513.
13. Tylicki L, Rutkowski B, Horl WH: Antioxidants: a possible role in kidneyprotection. Kidney Blood Press Res, 2003; 26(5-6): 303-1414.
14. Aruoma OI, Halliwell B, Hoey BM, Butler J: The antioxidant action ofN-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med, 1989; 6(6):593-9715.
15. Zicha J, Dobesova Z, Kunes J: Antihypertensive mechanisms of chroniccaptopril or N-acetylcysteine treatment in L-NAME hypertensive rats. Hypertens Res, 2006; 29(12): 1021-2716.
16. Rauchova H, Pechanova O, Kunes J et al: Chronic N-acetylcysteine administrationprevents development of hypertension in N(omega)-nitro-L-arginine methyl ester-treated rats: The role of reactive oxygen species. Hypertens Res, 2005; 28(5): 475-8217.
17. Dounousi E, Papavasiliou E, Makedou A et al: Oxidative stress is progressivelyenhanced with advancing stages of CKD. Am J Kidney Dis,2006; 48: 752-6018.
18. Hakim FA, Pflueger A: Role of oxidative stress in diabetic kidney disease. Med Sci Monit, 2010; 16(2): RA37-4819.
19. Pflueger A, Abramowitz D, Calvin AD: Role of oxidative stress in contrast-induced acute kidney injury in diabetes mellitus. Med Sci Monit,2009; 15(6): RA125-3620.
20. Ceballos-Picot I, Witko-Sarsat V, Merad-Boudia M et al: Glutathione antioxidantsystem as a marker of oxidative stress in chronic renal failure. Free Radic Biol Med, 1996; 21(6): 845-5321.
21. Mills BJ, Weiss MM, Lang CA et al: Blood glutathione and cysteine changesin cardiovascular disease. J Lab Clin Med, 2000; 135(5): 396-40122.
22. Boesgaard S, Aldershvile J, Poulsen HE et al: N-acetylcysteine inhibitsangiotensin converting enzyme in vivo. J Pharmacol Exp Ther, 1993;265(3): 1239-4423.
23. Tylicki L, Renke M, Rutkowski P et al: Effects of N-Acetylcysteine onAngiotensin-Converting Enzyme Plasma Activity in Patients with ChronicKidney Diseases. Blood Purif, 2008; 26(4): 35424.
24. Loske C, Neumann A, Cunningham AM et al: Cytotoxicity of advancedglycation endproducts is mediated by oxidative stress. J Neural Transm,1998; 105(8-9): 1005-1525.
25. Tian N, Rose RA, Jordan S et al: N-Acetylcysteine improves renal dysfunction, ameliorates kidney damage and decreases blood pressure insalt-sensitive hypertension. J Hypertens, 2006; 24(11): 2263-7026.
26. Agarwal R, Andersen MJ: Prognostic importance of ambulatory bloodpressure recordings in patients with chronic kidney disease. Kidney Int,2006; 69(7): 1175-8027.
27. Martina V, Masha A, Gigliardi V et al: Long-term N-acetylcysteine andL-arginine administration reduces endothelial activation and systolicblood pressure in hypertensive patients with type 2 diabetes. DiabetesCare, 2008; 31: 940-4428.
28. Rubanyi G: Endothelium-derived relaxing and contracting factors. JCell Biochem, 1991; 47: 27-3629.
29. Schmieder R, Schrader J, Zidek W et al: Low-grade albuminuria andcardiovascular risk: what is the evidence? Clin res Cardiol, 2007; 96:247-5730.
30. Gerstein H, Mann J, Yi Q et al: HOPE Study Investigators. Albuminuriaand risk of cardiovascular events, death, and heart failure in diabeticand nondiabetic individuals. JAMA, 2001; 286: 421-2631.
31. Yenicerioglu Y, Yilmaz O, Sarioglu S et al: Effects of N-acetylcysteine onradiocontrast nephropathy in rats. Scand J Urol Nephrol, 2006; 40(1):63-6932.
32. Sahin G, Yalcin AU, Akcar N: Effect of N-acetylcysteine on endothelialdysfunction in dialysis patients. Blood Purif, 2007; 25(4): 309-1533.
33. Andrews N, Prasad A, Quyyumi A: N-acetylcysteine improves coronaryand peripheral vascular function. J Am Coll Cardiol, 2001; 37: 117-2334.
34. Hashimoto S, Gon Y, Matsumoto K et al: N-acetylcysteine attenuatesTNF-alpha-induced p38 MAP kinase activation and p38 MAP kinasemediatedIL-8 production by human pulmonary vascular endothelialcells. Br J Pharmacol, 2001; 132: 270-7635.
35. Tepel M, van der Giet M, Statz M et al: The antioxidant acetylcysteinereduces cardiovascular events in patients with end-stage renal failure:a randomized, controlled trial. Circulation, 2003; 107(7): 992-9536.
36. Webb JG, Pate GE, Humphries KH et al: A randomized controlled trialof intravenous N-acetylcysteine for the prevention of contrast-inducednephropathy after cardiac catheterization: lack of effect. Am Heart J,2004; 148(3): 422-2937.
37. Sharif M, Bayraktutan U, Young I, Soong C: N-Acetylcysteine Does NotImprove the Endothelial and Smooth Musele Function in the HumanSaphenous Vein. Vasc Endovasc Surg, 2007; 41: 239-4538.
38. Miner SE, Dzavik V, Nguyen-Ho P et al: N-acetylcysteine reduces contrast-associated nephropathy but not clinical events during long-termfollow-up. Am Heart J, 2004; 148(4): 690-9539.
39. Spapen H, Diltoer M, Nguyen D et al: Effects of N-acetylcysteine on microalbuminuriaand organ failure in acute severe sepsis: results of a pilotstudy. Chest, 2005; 127: 1413-1940.
40. Burgunder JM, Varriale A, Lauterburg BH: Effect of N-acetylcysteineon plasma cysteine and glutathione following paracetamol administration. Eur J Clin Pharmacol, 1989; 36(2): 127-3141.
41. Kleinveld HA, Demacker PN, Stalenhoef AF: Failure of N-acetylcysteineto reduce low-density lipoprotein oxidizability in healthy subjects. EurJ Clin Pharmacol, 1992; 43(6): 639-4242.
42. Lynch R, Robertson R: Anaphylactoid reactions to intravenousN-acetylcysteine: a prospective case controlled study. Accid EmergNurs, 2004; 12: 10-1543.
43. Dierkes J, Domröse U, Westphal S et al: Cardiac troponin T predicts mortality in patients with end-stage renal disease. Circulation, 2000;102: 1964-6944.
44. Moustapha A, Naso A, Nahlawi M: Prospective study of hyperhomocysteinemiaas an adverse cardiovascular risk factor in end-stage renal disease. Circulation, 1997; 97: 138-4145.
45. Ventura P, Panini R, Pasini M et al: N-Acetylcysteine reduces homocysteineplasma levels after single intravenous administration by increasingthiols urinary excretion. Pharmacol Res, 1999; 40: 345-50